
Stryker Corporation SYK
$ 312.01
-1.41%
Quarterly report 2026-Q1
added 05-11-2026
Stryker Corporation Gross Profit 2011-2026 | SYK
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Stryker Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.63 B | 4.17 B | 13.1 B | 11.6 B | 11 B | 9.06 B | 9.7 B | 8.94 B | 8.17 B | 7.5 B | 6.6 B | 6.38 B | 6.04 B | 5.88 B | 5.5 B | 5.03 B | 4.54 B | 4.59 B | 4.14 B | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.1 B | 4.14 B | 7.18 B |
Quarterly Gross Profit Stryker Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.81 B | 3.85 B | 3.84 B | 3.74 B | 3.52 B | 3.42 B | 3.33 B | 3.16 B | 3.18 B | 3.02 B | - | 2.78 B | 2.83 B | 2.73 B | 3.04 B | 2.64 B | 2.77 B | 2.51 B | 2.72 B | 2.46 B | 1.55 B | 2.33 B | 2.7 B | 2.33 B | 2.38 B | 2.28 B | 2.46 B | 2.16 B | 2.19 B | 2.14 B | 2.24 B | 1.98 B | 1.99 B | 1.96 B | 2.09 B | 1.87 B | 1.84 B | 1.69 B | 1.82 B | 1.62 B | 1.6 B | 1.55 B | 1.72 B | 1.56 B | 1.55 B | 1.53 B | 1.62 B | 1.47 B | 1.48 B | 1.48 B | 1.59 B | 1.4 B | 1.43 B | 1.45 B | 1.48 B | 1.36 B | 1.33 B | 1.33 B | 1.23 B | 1.22 B | 1.22 B | 1.11 B | 1.1 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.85 B | 1.1 B | 2.16 B |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
26.6 M | $ 4.35 | 1.16 % | $ 163 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
275 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
22.7 M | $ 11.65 | 1.79 % | $ 330 M | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
IRIDEX Corporation
IRIX
|
19.2 M | $ 1.02 | 0.99 % | $ 17.3 M | ||
|
Alphatec Holdings
ATEC
|
532 M | $ 8.04 | -2.84 % | $ 1.21 B | ||
|
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
18 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
5.52 M | $ 2.29 | - | $ 50.5 M | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
LENSAR
LNSR
|
14.1 M | $ 5.95 | -2.38 % | $ 71.2 M | ||
|
Cytosorbents Corporation
CTSO
|
26.5 M | $ 0.47 | 2.16 % | $ 29.2 M | ||
|
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.54 | -0.65 % | $ 62.7 M | ||
|
OrthoPediatrics Corp.
KIDS
|
173 M | $ 17.91 | -2.5 % | $ 420 M | ||
|
Delcath Systems
DCTH
|
73.4 M | $ 10.83 | -1.77 % | $ 388 M | ||
|
Myomo
MYO
|
26.9 M | $ 1.02 | -0.97 % | $ 42.7 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
LivaNova PLC
LIVN
|
940 M | $ 75.68 | 2.51 % | $ 4.13 B | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Orthofix Medical
OFIX
|
566 M | $ 9.57 | -10.98 % | $ 379 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | ||
|
MiMedx Group
MDXG
|
346 M | $ 3.67 | 1.24 % | $ 542 M | ||
|
Profound Medical Corp.
PROF
|
11.4 M | $ 6.89 | 0.88 % | $ 208 M | ||
|
Electromed
ELMD
|
50 M | $ 38.09 | -0.34 % | $ 322 M | ||
|
Butterfly Network
BFLY
|
45.7 M | $ 4.57 | 2.13 % | $ 1.13 B | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | ||
|
Sintx Technologies
SINT
|
461 K | $ 2.43 | 1.67 % | $ 6.74 M | ||
|
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
1.02 B | $ 85.48 | 0.79 % | $ 11.6 B | ||
|
Insulet Corporation
PODD
|
1.94 B | $ 153.42 | -0.94 % | $ 10.8 B | ||
|
CONMED Corporation
CNMD
|
750 M | $ 36.13 | -3.02 % | $ 1.12 B | ||
|
Inspire Medical Systems
INSP
|
779 M | $ 42.27 | -3.58 % | $ 1.24 B | ||
|
Integer Holdings Corporation
ITGR
|
500 M | $ 91.06 | 1.99 % | $ 3.16 B | ||
|
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
4.73 B | $ 87.65 | 2.18 % | $ 51.3 B | ||
|
TransMedics Group
TMDX
|
363 M | $ 70.26 | 1.91 % | $ 2.39 B |